Revisión sobre patogénesis, epidemiología y clínica | 27 DIC 23

Dengue

Ante el aumento de casos de Dengue publicamos una revisión sobre el tema
Autor/a: Joshua M. Wong, Laura E. Adams, DVM, Anna P. Durbin, Jorge L. Mu~noz-Jordan y otros Pediatrics. 2022;149(6):e2021055522
INDICE:  1. Texto principal | 2. Texto principal
Texto principal

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504–507

2. Messina JP, Brady OJ, Golding N, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019;4(9):1508–1515

3. Yang X, Quam MBM, Zhang T, Sang S. Global burden for dengue and the evolving pattern in the past 30 years. J Travel Med. 2021;28(8):taab146

4. San Martın JL, Brathwaite O, Zambrano B, et al. The epidemiology of dengue in the Americas over the last three decades: a worrisome reality. Am J Trop Med Hug. 2010;82(1):128–135

5. Pan American Health Organization. Dengue. Available at: https://www.paho.org/data/ index.php/en/mnu-topics/indicadoresdengue-en.html. Accessed October 12, 2021

6. Dos Santos TH, Martin JLS, Castellanos LG, Espinal MA. Dengue in the Americas: Honduras’ worst outbreak. Lancet. 2019;394(10215):2149

7. Wilder-Smith A. Risk of dengue in travelers: implications for dengue vaccination. Curr Infect Dis Rep. 2018;20(12):50

8. Schwartz E, Weld LH, Wilder-Smith A, et al; GeoSentinel Surveillance Network. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006. Emerg Infect Dis. 2008;14(7):1081–1088

9. Shihada S, Emmerich P, Thome-Bolduan C, et al. Genetic diversity and new lineages of dengue virus serotypes 3 and 4 in returning travelers, Germany, 2006- 2015. Emerg Infect Dis. 2017;23(2): 272–275

10. Martinez DR, Yount B, Nivarthi U, et al. Antigenic variation of the dengue virus 2 genotypes impacts the neutralization activity of human antibodies in vaccinees. Cell Rep. 2020;33(1):108226

11. Paz-Bailey G, Adams L, Wong JM, et al. Dengue vaccine: recommendations of the advisory committee on immunization practices, United States, 2021. MMWR Recomm Rep. 2021;70(6):1–16

12. Sharp TM, Ryff KR, Santiago GA, Margolis HS, Waterman SH. Lessons learned from dengue surveillance and research, Puerto Rico, 1899-2013. Emerg Infect Dis. 2019;25(8):1522–1530

13. Rivera A, Adams LE, Sharp TM, Lehman JA, Waterman SH, Paz-Bailey G. Travel associated and locally acquired dengue cases - United States, 2010-2017. MMWR Morb Mortal Wkly Rep. 2020;69(6): 149–154

14. Centers for Disease Control and Prevention NCfEaZIDN. Division of vector-borne diseases (DVBD), dengue: statistics and maps. Available at: https://www.cdc.gov/ dengue/statistics-maps/index.html. Accessed October 18, 2021

15. Johnson TL, Haque U, Monaghan AJ, et al. Modeling the environmental suitability for Aedes (Stegomyia) aegypti and Aedes (Stegomyia) albopictus (Diptera: Culicidae) in the contiguous United States. J Med Entomol. 2017;54(6):1605–1614

16. Thomas DL, Santiago GA, Abeyta R, et al. Reemergence of dengue in southern Texas, 2013. Emerg Infect Dis. 2016; 22(6):1002–1007

17. Kraemer MU, Sinka ME, Duda KA, et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. eLife. 2015;4:e08347

18. Brunkard JM, Robles Lopez JL, Ramirez J, et al. Dengue fever seroprevalence and risk factors, Texas-Mexico border, 2004. Emerg Infect Dis. 2007;13(10): 1477–1483

19. Ramos MM, Mohammed H, Zielinski Gutierrez E, et al; Dengue Serosurvey Working Group. Epidemic dengue and dengue hemorrhagic fever at the Texas Mexico border: results of a household based seroepidemiologic survey, December 2005. Am J Trop Med Hyg. 2008; 78(3):364–369

20. Campbell LP, Luther C, Moo-Llanes D, Ramsey JM, Danis-Lozano R, Peterson AT. Climate change influences on global distributions of dengue and chikungunya virus vectors. Philos Trans R Soc Lond B Biol Sci. 2015;370(1665):20140135

21. Barrera R, Amador M, MacKay AJ. Population dynamics of Aedes aegypti and dengue as influenced by weather and human behavior in San Juan, Puerto Rico. PLoS Negl Trop Dis. 2011;5(12): e1378

22. Soneja S, Tsarouchi G, Lumbroso D, Tung DK. A review of dengue’s historical and future health risk from a changing climate. Curr Environ Health Rep. 2021;8(3):245–265

23. Eder M, Cortes F, Teixeira de Siqueira Filha N, et al. Scoping review on vectorborne diseases in urban areas: transmission dynamics, vectorial capacity and co-infection. Infect Dis Poverty. 2018;7(1):90

24. Reiter P, Lathrop S, Bunning M, et al. Texas lifestyle limits transmission of dengue virus. Emerg Infect Dis. 2003;9(1):86–89

25. Abdul-Ghani R, Mahdy MAK, Al-Eryani SMA, et al. Impact of population displacement and forced movements on the transmission and outbreaks of Aedes-borne viral diseases: dengue as a model. Acta Trop. 2019;197:105066

26. Gubler DJ. Dengue, urbanization and globalization: the unholy trinity of the 21(st) Century. Trop Med Health. 2011;39(4 Suppl):3–11

27. Teixeira MG, Barreto ML, Costa MC, Ferreira LDA, Vasconcelos PFC, Cairncross S. Dynamics of dengue virus circulation: a silent epidemic in a complex urban area. Trop Med Int Health. 2002;7(9):757–762

28. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11(3):480–496

29. Estallo EL, Carbajo AE, Grech MG, et al. Spatio-temporal dynamics of dengue 2009 outbreak in Cordoba City, Argentina. Acta Trop. 2014;136:129–136

30. Wilder-Smith A, Ooi E-E, Horstick O, Wills B. Dengue. Lancet. 2019;393(10169): 350–363

31. Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue. N Engl J Med. 2012;366(15): 1423–1432

32. Snow GE, Haaland B, Ooi EE, Gubler DJ. Review article: research on dengue during World War II revisited. Am J Trop Med Hyg. 2014;91(6):1203–1217

33. Sabin AB. Research on dengue during World War II. Am J Trop Med Hyg. 1952;1(1):30–50

34. Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis. 2013;7(8):e2357

35. Anderson KB, Gibbons RV, Cummings DAT, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014;209(3): 360–368

36. Halstead SB, Nimmannitya S, Cohen SN. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med. 1970;42(5):311–328

37. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg. 1988;38(2): 411–419

38. Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007; 5(7):518–528

39. Fernandez-Garcıa L, Angulo J, Ramos H, et al. The internal ribosome entry site of the Dengue virus mRNA is active when cap-dependent translation initiation is inhibited. J Virol. 2020;95(5):e01998-20

40. Cervantes-Salazar M, Angel-Ambrocio AH, Soto-Acosta R, et al. Dengue virus NS1 protein interacts with the ribosomal protein RPL18: this interaction is required for viral translation and replication in Huh-7 cells. Virology. 2015;484:113–126

41. Glasner DR, Puerta-Guardo H, Beatty PR, Harris E. The good, the bad, and the shocking: the multiple roles of dengue virus nonstructural protein 1 in protection and pathogenesis. Annu Rev Virol. 2018;5(1):227–253

42. Durbin AP. Dengue vascular leak syndrome: insights into potentially new treatment modalities. J Clin Invest. 2019;129(10):4072–4073

43. Weiskopf D, Angelo MA, de Azeredo EL, et al. Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD81 T cells. Proc Natl Acad Sci USA. 2013;110(22):E2046–E2053

44. Zellweger RM, Eddy WE, Tang WW, Miller R, Shresta S. CD81 T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J Immunol. 2014;193(8):4117–4124

45. Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science. 2017;358(6365):929–932

46. Katzelnick LC, Harris E; Participants in the Summit on Dengue Immune Correlates of Protection. Immune correlates of protection for dengue: state of the art and research agenda. Vaccine. 2017;35(36):4659–4669

47. Katzelnick LC, Narvaez C, Arguello S, et al. Zika virus infection enhances future risk of severe dengue disease. Science. 2020;369(6507):1123–1128

48. Flasche S, Jit M, Rodrıguez-Barraquer I, et al. The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live attenuated dengue vaccine (Dengvaxia): a model comparison study. PLoS Med. 2016;13(11):e1002181

49. Sharp TM, Anderson KB, Katzelnick LC, et al. Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation. Lancet Infect Dis. 2022;22(2):e42–e51

50. Grange L, Simon-Loriere E, Sakuntabhai A, Gresh L, Paul R, Harris E. Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections. Front Immunol. 2014;5:280

51. Centers for Disease Control and Prevention. Dengue clinical case management clinician pocket guide. Available at: https://www.cdc.gov/dengue/resources/ DengueCheatSheet_ENG-P.pdf. Accessed November 8, 2021

52. Regional Arboviral Disease Program. Algorithms for the Clinical Management of Dengue Patients. Washington D.C.: Pan American Health Organization (PAHO); 2020.

53. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health Information for International Travel. New York: Oxford University Press; 2017

54. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005;353(9): 877–889

55. Lam PK, Tam DT, Diet TV, et al. Clinical characteristics of dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital. Clin Infect Dis. 2013;57(11):1577–1586

56. Santiago GA, Vergne E, Quiles Y, et al. Analytical and clinical performance of the CDC real time RT-PCR assay for detection and typing of dengue virus. PLoS Negl Trop Dis. 2013;7(7): e2311

57. Centers for Disease Control and Prevention. Dengue for Healthcare Providers: Testing Guidance. Available at: https:// www.cdc.gov/dengue/healthcareproviders/testing/testing-guidance.html. Accessed June 30, 2021

58. Hunsperger EA, Mu~noz-Jordan J, Beltran M, et al. Performance of dengue diagnostic tests in a single-specimen diagnostic algorithm. J Infect Dis. 2016;214(6):836–844

59. Munoz-Jordan JL. Diagnosis of Zika virus infections: challenges and opportunities. J Infect Dis. 2017;216(suppl_10): S951–S956

60. Lindsey NP, Staples JE, Powell K, et al. Ability to serologically confirm recent Zika virus infection in areas with varying past incidence of dengue virus infection in the United States and US territories in 2016. J Clin Microbiol. 2017;56(1): e01115–e01117

61. Sharp TM, Fischer M, Mu~noz-Jordan JL, et al. Dengue and Zika virus diagnostic testing for patients with a clinically compatible illness and risk for infection with both viruses. MMWR Recomm Rep. 2019;68(1):1–10

62. Food and Drug Administration K100534 InBios DENV detect IgM capture ELISA; evaluation of automatic class III designation. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K100534.pdf. Accessed November 1, 2021

63. Food and Drug Administration (FDA). 510(k) substantial equivalence determination decision summary; K181473 InBios dengue virus NS1 antigen. 2018.

64. Goncalves A, Peeling RW, Chu MC, et al. Innovative and new approaches to laboratory diagnosis of Zika and dengue: a meeting report. J Infect Dis. 2018;217(7):1060–1068

65. Harapan H, Michie A, Sasmono RT, Imrie A. Dengue: a minireview. Viruses. 2020;12(8):829

66. Centers for Disease Control and Prevention. Dengue Case Management. Available at: https://www.cdc.gov/dengue/ resources/dengue-clinician-guide_508. pdf. Accessed October 21, 2021

67. Nasir NH, Mohamad M, Lum LCS, Ng CJ. Effectiveness of a fluid chart in outpatient management of suspected dengue fever: a pilot study. PLoS One. 2017;12(10):e0183544

68. Harris E, Perez L, Phares CR, et al. Fluid intake and decreased risk for hospitalization for dengue fever, Nicaragua. Emerg Infect Dis. 2003;9(8):1003–1006

69. Pan American Health Organization (PAHO). Self-learning course: clinical diagnosis and management of dengue (2021). Available at: https://www. campusvirtualsp.org/en/course/selflearning-course-clinical-diagnosis-andmanagement-dengue-2021. Accessed November 1, 2021

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024